Volume 11, Number 1—January 2005
Dispatch
Mycobacterium lentiflavum Infection in Immunocompetent Patient
Chiara Molteni*, Lidia Gazzola*, Miriam Cesari*, Alessandra Lombardi*, Franco Salerno*, Enrico Tortoli†, Luigi Codecasa‡, Valeria Penati‡, Fabio Franzetti*, and Andrea Gori*
Table
Summary of clinical features for 14 patients with Mycobacterium lentiflavum infection*
| Patient no. (ref. no.) | Age | Sex | Concomitant disease | Intercurrent treatment | Side of infection | Susceptibility test | Antimycobacterial therapy | Clinical outcome |
|---|---|---|---|---|---|---|---|---|
| 1 (3) | 19 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery (resolved) |
| 2 (4) | 42 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery |
| 3 (4) | 33 mo | M | No | No | Cervical lymph node | No | Surgical excision | Recovery |
| 4 (2) | 6 y | F | No | No | Cervical lymph node | ND | Rif, clm/3 wk surgical excision | Recovery |
| 5 (2) | 4 y | F | ND | ND | Cervical lymph node | ND | Inh, rif/† surgical excision | Recovery |
| 6 (2) | 4 y | M | ND | ND | Cervical lymph node | ND | surgical excision | Recovery |
| 7 (6) | 3 y | M | No | No | Cervical lymph node | ND | Clm, eth/6mo | Persistent suppuration |
| 8 (I7) | 52 y | F | Antisynthetase syndrome | Corticosteroid | Synovial fluid of wrist | inh R, rif R, str R, eth R, pza R, cys S | inh, rif, eth, pza/† fus, levo, clm/1wk | Exitus |
| 9 (8) | 49 y | M | HIV infection | HAART | Blood, lung | clm S, rib S | clm, rib, eth/4mo | Recovery |
| 10 (1) | 85 y | F | Diabetes mellitus | ND | Thoracic vertebrae | No | inh, rif, pza/3mo Inh, rif/6mo | Improvement |
| 11 (2) | 58 y | M | Rheumatoid arthritis | Corticosteroid | Lung | ND | inh, rib, eth, pza/4mo | No improvement |
| 12 (2) | 61 y | F | COPD, ovarian carcinoma | Reiterated chemotherapy | Lung | ND | rif, inh, pza/† rib, eth, clm, cip/† | No improvement (unchanged) |
| 13 (2) | 45 y | M | HIV infection, NHL | HAART | Hepatic nodular lesion | ND | rib, clm, eth, cip/2 mo Rib, clm/4mo | Recovery |
| 14 (Molteni) | 70 y | F | COPD, lung fibrodystrophy | No | Lung | inh R, str R, rif R, amik R, km R, pza R, oflox R, clm S, eth S, cys S, ter S, rib S | cip, inh/1mo inh, pza, eth, rif/3mo clm/3mo clm, eth, rib, cip/2wk | No improvement |
*M, male; F, female; ND, not done; COPD, chronic obstructive pulmonary disease; HAART, higly active antiretroviral therapy; amik, amikacin; clm, clarithromycin; cys, cycloserine; eth, ethambutol, fus, fusidic acid; inh, isoniazid; km, kanamycin; levo, levofloxacin; oflox, ofloxacin, pza, pyrazinamide; rib, rifabutin; rif, rifampin, str, streptomycin; ter, terizidon.
†Treatment duration not determined.
References
- Springer B, Wu WK, Bodmer T, Haase G, Pfyffer GE, Kroppenstedt RM, Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol. 1996;34:1100–7.PubMedGoogle Scholar
- Tortoli E, Piersimoni C, Kirschner P, Bartoloni A, Burrini C, Lacchini, et al. Characterization of mycobacteria isolates phylogenetically related to, but different from Mycobacterium simiae. J Clin Microbiol. 1997;35:697–702.PubMedGoogle Scholar
- Cabria F, Torres MV, Garcia-Cia JI, Dominguez-Garrido MN, Esteban J, Jimenez MS. Cervical lymphadenitis caused by Mycobacterium lentiflavum. Pediatr Infect Dis. 2002;21:574–5. DOIPubMedGoogle Scholar
- Haase G, Kentrup H, Skopnik H, Springer B, Böttger C. Mycobacterium lentiflavum: an etiological agent of cervical lymphadenitis. Clin Infect Dis. 1997;25:1245–6. DOIPubMedGoogle Scholar
- Tortoli E, Bartoloni A, Erba ML, Levre E, Lombardi N, Mantella A, Human infections due to Mycobacterium lentiflavum. J Clin Microbiol. 2002;40:728–9. DOIPubMedGoogle Scholar
- Uria MJ, Garcia J, Menendez JJ, Jimenez MS. Mycobacterium lentiflavum infection: case history and review of the medical literature. Enferm Infecc Microbiol Clin. 2003;21:274–5.PubMedGoogle Scholar
- Ibanez R, Serrano-Heranz R, Jimenez-Palop M, Roman C, Corteguera M, Jimenez S. Disseminated infection caused by slow-growing Mycobacterium lentiflavum. Eur J Clin Microbiol Infect Dis. 2002;21:691–2. DOIPubMedGoogle Scholar
- Niobe SN, Bebear CM, Clerc M, Pellegrin JL, Bebear C, Maugein J. Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol. 2001;39:2030–2. DOIPubMedGoogle Scholar
- Galarraga MC, Torreblanca A, Jimenez MS. Isolation of Mycobacterium lentiflavum in a case of suspected lung cancer. Enferm Infecc Microbiol Clin. 2002;20:93–4.PubMedGoogle Scholar
- Migliori GB, Centis R, Fattorini L, Besozzi G, Saltini C, Orefici G, Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. Eur Respir J. 2003;21:129–34. DOIPubMedGoogle Scholar
Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.